Pulmonx Reports Record Third Quarter 2023 Financial Results

Rhea-AI Summary

Pulmonx Corporation reported record worldwide revenue of $17.7 million in Q3 2023, a 31% increase YoY. U.S. revenue reached $11.8 million, representing 41% YoY growth. Gross margin was 74%. The company added 15 new U.S. treatment centers for Zephyr Valves and received reimbursement approval in Japan for severe COPD/emphysema patients.

Positive

• Pulmonx achieved record worldwide revenue of $17.7 million in Q3 2023, a 31% increase over the same period last year.
• U.S. revenue for Pulmonx reached $11.8 million in Q3 2023, representing a 41% year-over-year growth.
• The company realized a gross margin of 74% in Q3 2023.
• Pulmonx added 15 new U.S. treatment centers for Zephyr Valves in Q3 2023.
• The Japanese Ministry of Health, Labour and Welfare approved reimbursement for the use of Zephyr Valves in severe COPD/emphysema patients in Japan.

Negative

• None.

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2023 ended September 30, 2023.

Recent Highlights

• Achieved record worldwide revenue of $17.7 million in the third quarter of 2023, a 31% increase over the same period last year and an increase of 29% on a constant currency basis
• Delivered a record $11.8 million in U.S. revenue in the third quarter of 2023, representing 41% year-over-year growth
• Realized gross margin of 74% in the third quarter of 2023
• Added 15 new U.S. treatment centers for Zephyr Valves in the third quarter 2023
• Approved for reimbursement by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the use of Zephyr Valves to treat severe COPD/emphysema patients in Japan
  

“Our record quarterly results were driven by strength in the U.S., reflective of traction we are seeing from our focused commercial strategy,” said Glen French, President, and Chief Executive Officer. “Awareness around the benefits of Zephyr Valve treatment continues to build as we remain intensely focused on improving the lives of more and more patients with severe COPD/emphysema.”

Third Quarter 2023 Financial Results
Total worldwide revenue in the third quarter of 2023 was $17.7 million, a 31% increase from $13.5 million in the third quarter of 2022 and a 29% increase on a constant currency basis. U.S. revenue was $11.8 million, a 41% increase from the third quarter of 2022. International revenue was $5.8 million, a 14% increase compared to the third quarter of 2022 and a 9% increase on a constant currency basis. The growth in revenue reflects continued commercial momentum and adoption of Zephyr Valve procedures.

Gross profit in the third quarter of 2023 was $13.0 million, compared to $10.2 million for the third quarter of 2022. Gross margin for the third quarter of 2023 was 74%, compared to 75% for the same period in 2022, reflecting higher inventory reserves in the quarter.

Operating expenses in the third quarter of 2023 were $28.2 million, compared to $24.1 million for the third quarter of 2022, representing an increase of 17%. The increase in operating expenses was primarily attributable to continued investments in our commercial activities, legal expenses, and higher stock-based compensation expense.

Net loss in the third quarter of 2023 was $14.9 million, or $0.39 per share, compared to a net loss of $14.2 million, or $0.38 per share, for the same period in 2022.

Adjusted EBITDA loss in the third quarter of 2023 was $9.0 million compared to $9.7 million for the same period in 2022.

Cash, cash equivalents, and marketable securities totaled $139.8 million as of September 30, 2023.

2023 Financial Outlook
Pulmonx is increasing its expectation for revenue in 2023 to now range from $67 million to $68 million, which represents approximately 25% to 27% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $64 million to $66 million.

The Company expects gross margin for the full year 2023 to be approximately 74%.

Pulmonx also continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $21 million of non-cash stock-based compensation.

Webcast and Conference Call Details
Pulmonx will host a conference call today, October 30, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures
To supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business.

Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx’s historical operating results.

The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.

Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below.

The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our commercial strategy to grow the adoption of our Zephyr Valve treatment and expand our global treatable market, our expectations regarding account activity and productivity, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, profitability, guidance for full year 2023, commercial momentum, physician engagement and awareness of the benefits of the Zephyr Valve, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q filed with the SEC on August 4, 2023, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System and StratX^® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Investor Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

Pulmonx Corporation Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2023				2022				2023				2022
Revenue		$	17,668			$	13,502			$	49,397			$	38,237
Cost of goods sold			4,639				3,350				13,045				9,556
Gross profit			13,029				10,152				36,352				28,681
Operating expenses
Research and development			4,220				4,366				14,184				11,494
Selling, general and administrative			23,985				19,717				70,184				61,197
Total operating expenses			28,205				24,083				84,368				72,691
Loss from operations			(15,176	)			(13,931	)			(48,016	)			(44,010	)
Interest income			1,490				477				4,027				781
Interest expense			(893	)			(286	)			(2,327	)			(707	)
Other income (expense), net			(262	)			(432	)			(316	)			(597	)
Net loss before tax			(14,841	)			(14,172	)			(46,632	)			(44,533	)
Income tax expense			59				—				323				107
Net loss		$	(14,900	)		$	(14,172	)		$	(46,955	)		$	(44,640	)
Net loss per share attributable to common stockholders, basic and diluted		$	(0.39	)		$	(0.38	)		$	(1.24	)		$	(1.21	)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted			38,119,824				37,190,352				37,838,822				37,001,136

Pulmonx Corporation Condensed Consolidated Balance Sheets (in thousands) (Unaudited)
	September 30,				December 31,
		2023				2022
Assets
Current assets:
Cash and cash equivalents	$	94,945			$	101,736
Restricted cash		236				231
Short-term marketable securities		21,537				39,402
Accounts receivable, net		10,091				8,677
Inventory		16,131				14,564
Prepaid expenses and other current assets		4,424				4,343
Total current assets		147,364				168,953
Long-term marketable securities		23,271				5,924
Long-term inventory		3,445				5,283
Property and equipment, net		4,065				4,694
Goodwill		2,333				2,333
Intangible assets, net		62				154
Right of use assets		4,061				5,806
Other long-term assets		415				529
Total assets	$	185,016			$	193,676
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	3,189			$	1,758
Accrued liabilities		13,684				13,276
Income taxes payable		—				19
Deferred revenue		85				120
Short-term debt		91				90
Current lease liabilities		3,436				3,229
Total current liabilities		20,485				18,492
Deferred tax liability		97				94
Long-term lease liabilities		1,537				3,849
Long-term debt		37,154				17,234
Total liabilities		59,273				39,669
Stockholders' equity:
Common stock		38				38
Additional paid-in capital		521,034				502,712
Accumulated other comprehensive income		1,944				1,575
Accumulated deficit		(397,273	)			(350,318	)
Total stockholders' equity		125,743				154,007
Total liabilities and stockholders' equity	$	185,016			$	193,676

Pulmonx Corporation Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change (in thousands) (Unaudited)
	Three Months Ended September 30,
		2023				2022			% Change			FX Impact %			Constant Currency % Change
United States	$	11,838			$	8,402			40.9	%		—	%		40.9	%
International		5,830				5,100			14.3	%		5.3	%		9.0	%
Total	$	17,668			$	13,502			30.9	%		2.1	%		28.8	%
	Nine Months Ended September 30,
		2023				2022			% Change			FX Impact %			Constant Currency % Change
United States	$	32,197			$	23,031			39.8	%		—	%		39.8	%
International		17,200				15,206			13.1	%		(0.2	)%		13.3	%
Total	$	49,397			$	38,237			29.2	%		(0.1	)%		29.3	%

Pulmonx Corporation Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA (in thousands) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
		2023				2022				2023				2022
GAAP Net loss	$	(14,900	)		$	(14,172	)		$	(46,955	)		$	(44,640	)
Depreciation and amortization		415				383				1,261				1,127
Stock-based compensation		6,003				4,302				16,503				12,198
Interest (income)/expense, net		(597	)			(191	)			(1,700	)			(74	)
Provision for income taxes		59				—				323				107
Adjusted EBITDA	$	(9,020	)		$	(9,678	)		$	(30,568	)		$	(31,282	)

FAQ

What was Pulmonx Corporation's worldwide revenue in Q3 2023?

Pulmonx Corporation reported worldwide revenue of $17.7 million in Q3 2023.

What was the growth rate of U.S. revenue for Pulmonx Corporation in Q3 2023?

U.S. revenue for Pulmonx Corporation grew by 41% in Q3 2023 compared to the same period last year.

What was Pulmonx Corporation's gross margin in Q3 2023?

Pulmonx Corporation achieved a gross margin of 74% in Q3 2023.

How many new U.S. treatment centers did Pulmonx Corporation add for Zephyr Valves in Q3 2023?

Pulmonx Corporation added 15 new U.S. treatment centers for Zephyr Valves in Q3 2023.

Did Pulmonx Corporation receive reimbursement approval in Japan for Zephyr Valves?

Yes, the Japanese Ministry of Health, Labour and Welfare approved reimbursement for the use of Zephyr Valves in severe COPD/emphysema patients in Japan.